Responses to anti-angiogenic therapies.
Vascular tumors occur in approximately 10% of infants, and range from small cherry-red lesions to large, life-threatening tumors. Although the majority of these tumors involute after several years, there are few therapeutic options and their use is limited by the risk of side-effects. The recent increase in understanding of angiogenesis has led to investigations of new antiangiogenic treatment options using models of vascular tumors in mice. These studies have demonstrated the success of a variety of antiangiogenic approaches, including systemic administration of the antiangiogenic proteins AGM-1470 and angiostatin or of the matrix metalloproteinase inhibitor batimastat, and gene gun therapy with interleukin-12. Although these trials provide further evidence of the role of angiogenesis in the enlargement of these vascular tumors, their potential utility and safety await future trials in patients.
Paller
A S
AS
Department of Pediatrics, Northwestern University Medical School, Chicago, Illinois, USA. apaller@nwu.edu
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D043168:Angiostatins; D000818:Animals; D003510:Cyclohexanes; D004195:Disease Models, Animal; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D010446:Peptide Fragments / Q000494:pharmacology; D010958:Plasminogen / Q000494:pharmacology; D012717:Sesquiterpenes / Q000494:pharmacology*; D012878:Skin Neoplasms / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D003510:Cyclohexanes; D010446:Peptide Fragments; D012717:Sesquiterpenes; D043168:Angiostatins; D010958:Plasminogen; D000077609:O-(Chloroacetylcarbamoyl)fumagillol